CDK4 and cancer: In addition, the treatment with these two BET-PROTACs reduced the expression levels of several pro-tumorigenic genes such as c-Myc, Cyclin-dependent kinase 4 (CDK4), cyclin D, B-cell lymphoma-extra large (Bcl-xL), XIAP, Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP), c-IAP2, interleukin-10 (IL-10), and BTK—most of which are NF-κB-target genes—and, at the same time, increased the levels of anti-cancer genes like NOXA, p21 and p27, thus showing a higher efficacy than OTX015 [218,219,220].